AAVXF:OTCMKTS
Abivax SA
US$ 139.00
0.00%
(0.00) Siku 1
9 Jul, 09:30:01 GMT -4 · USD
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya AAVXF...
Mtaji wa soko
6.63B
Wastani wa kiasi cha mauzo
0.00
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
US$ 139.00
Chini kwa wiki 52
US$ 71.26
Beta
3.09
Hisa za wawekezaji
87.53M
Idadi ya wafanyakazi
98
Mtaji wa soko
6.63B
Wastani wa kiasi cha mauzo
0.00
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
US$ 139.00
Chini kwa wiki 52
US$ 71.26
Beta
3.09
Hisa za wawekezaji
87.53M
Idadi ya wafanyakazi
98
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
https://www.dars.gov.et/
·
siku 5 zilizopita
ABVX Q2 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Keeps Spending on Pipeline
Wasifu
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Kuhusu Abivax SA
Afisa Mkuu Mtendaji (CEO)Marc de Garidel | Hartmut J. Ehrlich
Wafanyakazi98
Lilianzishwa4 Des 2013
Makao makuu-
Sekta-
Tovutiabivax.com